The global controlled substance market size accounted for USD 93.70 billion in 2024, grew to USD 98.70 billion in 2025 and is expected to be worth around USD 157.64 billion by 2034, registering a healthy CAGR of 5.34% between 2024 and 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Controlled Substance Market
5.1. COVID-19 Landscape: Controlled Substance Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Controlled Substance Market, By Drug
8.1. Controlled Substance Market, by Drug, 2024-2034
8.1.1 Opioids
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Stimulant
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Depressants
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Cannabinoids
8.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Controlled Substance Market, By Application
9.1. Controlled Substance Market, by Application, 2024-2034
9.1.1. ADHD
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Pain Management
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Depression
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Sleep Disorder
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.6. Cough Suppression
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Anxiety
9.1.7.1. Market Revenue and Forecast (2021-2034)
9.1.8. Seizures
9.1.8.1. Market Revenue and Forecast (2021-2034)
9.1.9. Others
9.1.9.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Controlled Substance Market, By Distribution
10.1. Controlled Substance Market, by Distribution, 2024-2034
10.1.1. Hospital Pharmacy
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Online Pharmacy
10.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Controlled Substance Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug (2021-2034)
11.1.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug (2021-2034)
11.2.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug (2021-2034)
11.3.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug (2021-2034)
11.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug (2021-2034)
11.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Distribution (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Distribution (2021-2034)
Chapter 12. Company Profiles
12.1. Merck & Co. Inc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Johnson & Johnson
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Orbis Biosciences
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Aradigm Corporation
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Corium International
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. G.W. Pharmaceuticals
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Lannett
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample